Q BioMed (QBIO) Rating Lowered to Neutral at Roth Capital

Q BioMed (OTCMKTS:QBIO) was downgraded by equities research analysts at Roth Capital from a “buy” rating to a “neutral” rating in a research note issued to investors on Thursday, The Fly reports. They currently have a $1.85 price objective on the stock, down from their prior price objective of $6.75. Roth Capital’s price objective indicates a potential downside of 5.13% from the company’s previous close.

Shares of OTCMKTS:QBIO traded up $0.13 during trading hours on Thursday, reaching $1.95. The stock had a trading volume of 38,124 shares, compared to its average volume of 42,801. Q BioMed has a 1 year low of $1.67 and a 1 year high of $5.90.

Q BioMed Company Profile

Q BioMed Inc, a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer.

Featured Article: What are the benefits of a balanced fund?

The Fly

Receive News & Ratings for Q BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Q BioMed and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit